OncoSil’s Fully Underwritten Offer Could Dilute Shareholders Amid Clinical Risks

Capital Raising Overview

OncoSil Medical Limited (ASX, OSL), a clinical-stage medical device company, has launched a fully underwritten non-renounceable entitlement offer to raise approximately $2 million. Eligible shareholders can subscribe for 1 new share for every 6.4 shares held at a discounted issue price of 68 cents per share. Each new share issued under the offer will also be accompanied by 1 new option exercisable at 90 cents until 30 June 2027.

In parallel, the company has secured commitments from sophisticated and professional investors for a placement expected to raise about $6 million. This placement includes the issue of new shares at the same price and attaching options, subject to shareholder approval. Bell Potter Securities Limited is acting as lead manager and underwriter for the entitlement offer and placement.

Use of Proceeds and Strategic Intent

The combined funds from the entitlement offer and placement, totaling up to $8 million before costs, will be allocated to several key areas. These include investment in OncoSil’s manufacturing facility, ongoing clinical activities such as the TRIPP FFX and PANCOSIL studies, market access initiatives, sales and marketing efforts, and general working capital. The capital injection aims to support the company’s transition from clinical development towards commercialisation.

Offer Structure and Shareholder Impact

The entitlement offer is non-renounceable, meaning shareholders cannot trade their rights. Eligible shareholders who fully subscribe for their entitlement may also apply for additional shares through a Top-Up Facility, which allows them to acquire shares not taken up by others. Any shortfall after the Top-Up Offer will be placed by the underwriter and sub-underwriters.

Notably, Pengana Capital Limited, the company’s largest substantial shareholder holding approximately 18.12%, has committed to fully take up its entitlement and sub-underwrite a significant portion of any shortfall. This could increase Pengana’s stake to a maximum of around 23.14% on an undiluted basis, subject to shareholder approvals and subscription levels.

Risks and Regulatory Considerations

OncoSil’s prospectus highlights the speculative nature of investing in a biotechnology company at this stage. Key risks include the need for additional funding beyond this raise, regulatory approvals in multiple jurisdictions, clinical trial outcomes, manufacturing scale-up challenges, and market acceptance of its OncoSil device. The company also faces intellectual property and product liability risks common to medical device developers.

The underwriting agreement includes termination rights for Bell Potter Securities in the event of adverse regulatory developments, material misstatements, or market disruptions. Shareholders are advised to carefully consider these risks and consult professional advisers before participating.

Next Steps and Timeline

The entitlement offer opens on 11 February 2026 and closes on 10 March 2026, with new shares and options expected to be issued on 17 March 2026. Trading of the new securities on ASX is anticipated to commence on 18 March 2026. Shareholder approval for the placement options and lead manager options will be sought at an extraordinary general meeting scheduled for 12 March 2026.

OncoSil’s board and management underscore the importance of this capital raising to fund the company’s growth trajectory and clinical development programs. The outcome of shareholder participation and approval votes will be closely watched by investors and market observers alike.